Skip to main content

EA2201 A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

NCT04751370

A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Associated Conditions

Anal Cancer

Principal Investigator

Sponsor

EA2201 NCI

To demonstrate that neoadjuvant nivolumab and ipilimumab in combination with short-course radiation will improve the pathologic complete response rate (pCR) in MSI-H/dMMR locally advanced rectal adenocarcinoma at TME.

This study is currently enrolling.